Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension;Efecto de la doxazosina de liberación modificada en la presión arterial, la resistencia a la insulina y la secreción de catecolaminas en pacientes con hipertensión arterial resistente verdadera

Medicina Clinica

Volumn 123, Issue 8, 2004, Pages 297-299

  García, Juan Diego Mediavilla ^a   Sabio, José Mario ^a   Fernández Torres, Celia ^a   Martínez, Luis Aliaga ^a   Jiménez Alonso, Juan ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Doxazosin; Insulin resistance; Resistant hypertension; Urinary catecholamines

Indexed keywords

ALDOSTERONE; CATECHOLAMINE; DOXAZOSIN; INSULIN; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CATECHOLAMINE RELEASE; CATECHOLAMINE URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PLASMA RENIN ACTIVITY; TREATMENT OUTCOME;

EID: 5644269231     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(04)74496-6     Document Type: Article

References (10)

1. The Seventh Report of the Joint National Committee on Prevention, Detection and Treatment of High Blood Pressure (JNC-VII). JAMA 2003;289:256-72.
2. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension. A prospective study. Hypertension 1998;31:712-8.
3. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-81.
4. Brown MK, Dickerson JE. Alpha block and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens 1995;13:701-7.
5. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
6. Hernández-del Rey R, Armario P, Martin-Baranera M, Sánchez P, Cárdenas G, Pardell H. Target-organ damage and cardiovascular risk profile in resistant hypertension. Blood Press Monit 1998;3:331-7.
7. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. J Cardiovasc Pharmacol 1999;33:791-7.
8. Donnelly R, Elliott HL, Howie CA, Sumner DJ, Reid JL. Vascular pressor responses in treated and untreated essential hypertension. J Cardiovasc Pharmacol 1990;16:191-6.
9. Mulatero P, Rabbia F, Milán A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldodosteronism. Hypertension 2002;40:897-902.
10. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosina. An update of its clinical Pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drug 1995;49:295-320.